Highlights Sensei Biotherapeutics, Inc.

Equities

SNSE

US81728A1088

Market Closed - Nasdaq Other stock markets 01:30:00 11/05/2024 am IST			5-day change	1st Jan Change
1.51 ^USD	-3.82%		-15.64%	+118.21%

09/05	Sensei Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
24/04	Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sensei Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting	25/04	CI
Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of Vista Within the Tumor Microenvironment	05/04	CI
North American Morning Briefing : Stocks Set for -2-	28/03	DJ
Sensei Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02	CI
Sensei Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2023	07/11	CI
Newtyn Partners, LP and Newtyn TE Partners, LP, managed by Newtyn Management, LLC cancelled the acquisition of remaining 93.48% stake in Sensei Biotherapeutics, Inc..	06/11	CI
Newtyn Partners, LP and Newtyn TE Partners, LP, managed by Newtyn Management, LLC made a proposal to acquire remaining 93.48% stake in Sensei Biotherapeutics, Inc. for $25 million.	03/11	CI
Sensei Biotherapeutics, Inc. to Present Initial Clinical Data from Dose Escalation Trial of SNS 101 At 2023 SITC Annual Meeting	25/23/25	CI
Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron's Libtayo	27/23/27	CI
Sensei Biotherapeutics, Inc. Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action	21/23/21	CI
Sensei Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2023	03/23/03	CI
Sensei Biotherapeutics, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101	01/23/01	CI
Sensei Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	09/23/09	CI
Sensei Biotherapeutics Says US FDA Approves Investigational New Drug Application for Cancer Drug Candidate SNS-101	20/23/20	MT
Sensei Biotherapeutics, Inc. Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for SNS-101, a Conditionally Active Vista-Blocking Antibody	20/23/20	CI
SENSEI BIOTHERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	29/23/29	AQ
Sensei Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	28/23/28	CI
Sensei Biotherapeutics Adopts Rights Agreement to Protect Stockholders	08/23/08	MT
Sensei Biotherapeutics, National Cancer Institute to Collaborate on SNS-101 Development; Shares Gain Premarket	06/23/06	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

SENSEI BIOTHERAPEUTICS : Mixed Q3; but cash cushion remains intact

November 10, 2022 at 05:29 pm IST